Finding 574584 (2023-006)

Material Weakness
Requirement
L
Questioned Costs
-
Year
2023
Accepted
2025-08-22
Audit: 364802

AI Summary

  • Core Issue: Endeavor failed to include all federal awards in the SEFA, specifically under the Coronavirus State and Local Fiscal Recovery Fund, leading to a misstated report.
  • Impacted Requirements: This finding violates Section 200.303 of the Uniform Guidance regarding internal controls and the requirement to prepare a complete SEFA as per 2 CFR section 200.510.
  • Recommended Follow-Up: Endeavor should enhance internal controls for reporting federal expenditures, including revising procedures and involving key stakeholders in the SEFA review process.

Finding Text

Finding 2023-006 – Reporting – SEFA Preparation Information of the federal program:Federal Grantor: United States Department of Health and Human Services Assistance Listing No.: 21.027, Coronavirus State and Local Fiscal Recovery Fund Criteria or specific requirement (including statutory, regulatory or other citation): Section 200.303 of the Uniform Guidance states the following regarding internal control: “The non-Federal entity must: (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).” The Uniform Guidance 2 CFR section 200.510 states, “(b) Schedule of expenditures of Federal awards. The auditee must also prepare a schedule of expenditures of federal awards (SEFA) for the period covered by the auditee’s financial statements which must include the total Federal awards expended as determined in accordance with §200.502 Basis for determining Federal awards expended.” Condition: Endeavor did not provide a complete and accurate listing of all federal awards in the SEFA. Cause:Endeavor did not include all funds expended under the Coronavirus State and Local Fiscal Recovery Fund on the SEFA. Effect or potential effect:The SEFA prepared by Endeavor in fiscal year 2023 was misstated but was subsequently corrected. Themisstated SEFA resulted in the improper identification of federal award major programs, and therefore resulted in a restatement of a previously issued Uniform Guidance report. Questioned costs:None Context:Expenditures for ALN 21.027 were understated by $1,399,999, which resulted in the program being identified as a major program upon inclusion of the costs. Identification as a repeat finding, if applicable:This finding is not a repeat finding. Recommendation:Endeavor should review its internal controls over the process of accumulating and reporting expenditures of federal awards to ensure a completed and accurate SEFA presentation. Views of responsible officials:The grant was received and expended during a period that overlapped fiscal years, and internal miscommunication led to its initial exclusion from the SEFA submitted for audit. Management will enhance the SEFA preparation process by revising its procedures and adding additional controls to monitor for completeness of the data. This will include comparisons to the prior year programs, enhancing the Company’s grant tracking process, and review of the SEFA with key stakeholders. Upon identification of the omission, management reviewed the grant activity and has taken corrective action to ensure proper inclusion in future SEFA reports.

Categories

Reporting

Other Findings in this Audit

  • 574483 2023-001
    Material Weakness
  • 574484 2023-002
    Material Weakness
  • 574485 2023-001
    Material Weakness
  • 574486 2023-002
    Material Weakness
  • 574487 2023-001
    Material Weakness
  • 574488 2023-005
    Significant Deficiency
  • 574489 2023-001
    Material Weakness
  • 574490 2023-005
    Significant Deficiency
  • 574491 2023-001
    Material Weakness
  • 574492 2023-002
    Material Weakness
  • 574493 2023-005
    Significant Deficiency
  • 574494 2023-005
    Significant Deficiency
  • 574495 2023-001
    Material Weakness
  • 574496 2023-005
    Significant Deficiency
  • 574497 2023-001
    Material Weakness
  • 574498 2023-001
    Material Weakness
  • 574499 2023-002
    Material Weakness
  • 574500 2023-005
    Significant Deficiency
  • 574501 2023-001
    Material Weakness
  • 574502 2023-002
    Material Weakness
  • 574503 2023-005
    Significant Deficiency
  • 574504 2023-005
    Significant Deficiency
  • 574505 2023-001
    Material Weakness
  • 574506 2023-001
    Material Weakness
  • 574507 2023-005
    Significant Deficiency
  • 574508 2023-001
    Material Weakness
  • 574509 2023-002
    Material Weakness
  • 574510 2023-004
    Material Weakness
  • 574511 2023-001
    Material Weakness
  • 574512 2023-001
    Material Weakness
  • 574513 2023-005
    Significant Deficiency
  • 574514 2023-001
    Material Weakness
  • 574515 2023-005
    Significant Deficiency
  • 574516 2023-001
    Material Weakness
  • 574517 2023-005
    Significant Deficiency
  • 574518 2023-001
    Material Weakness
  • 574519 2023-005
    Significant Deficiency
  • 574520 2023-001
    Material Weakness
  • 574521 2023-005
    Significant Deficiency
  • 574522 2023-001
    Material Weakness
  • 574523 2023-005
    Significant Deficiency
  • 574524 2023-001
    Material Weakness
  • 574525 2023-005
    Significant Deficiency
  • 574526 2023-001
    Material Weakness
  • 574527 2023-005
    Significant Deficiency
  • 574528 2023-001
    Material Weakness
  • 574529 2023-005
    Significant Deficiency
  • 574530 2023-001
    Material Weakness
  • 574531 2023-005
    Significant Deficiency
  • 574532 2023-001
    Material Weakness
  • 574533 2023-005
    Significant Deficiency
  • 574534 2023-001
    Material Weakness
  • 574535 2023-005
    Significant Deficiency
  • 574536 2023-001
    Material Weakness
  • 574537 2023-001
    Material Weakness
  • 574538 2023-001
    Material Weakness
  • 574539 2023-001
    Material Weakness
  • 574540 2023-001
    Material Weakness
  • 574541 2023-001
    Material Weakness
  • 574542 2023-002
    Material Weakness
  • 574543 2023-003
    Material Weakness
  • 574544 2023-002
    Material Weakness
  • 574545 2023-001
    Material Weakness
  • 574546 2023-001
    Material Weakness
  • 574547 2023-005
    Significant Deficiency
  • 574548 2023-001
    Material Weakness
  • 574549 2023-005
    Significant Deficiency
  • 574550 2023-001
    Material Weakness
  • 574551 2023-005
    Significant Deficiency
  • 574552 2023-001
    Material Weakness
  • 574553 2023-002
    Material Weakness
  • 574554 2023-005
    Significant Deficiency
  • 574555 2023-001
    Material Weakness
  • 574556 2023-005
    Significant Deficiency
  • 574557 2023-001
    Material Weakness
  • 574558 2023-005
    Significant Deficiency
  • 574559 2023-001
    Material Weakness
  • 574560 2023-002
    Material Weakness
  • 574561 2023-001
    Material Weakness
  • 574562 2023-002
    Material Weakness
  • 574563 2023-001
    Material Weakness
  • 574564 2023-005
    Significant Deficiency
  • 574565 2023-002
    Material Weakness
  • 574566 2023-001
    Material Weakness
  • 574567 2023-002
    Material Weakness
  • 574568 2023-001
    Material Weakness
  • 574569 2023-001
    Material Weakness
  • 574570 2023-001
    Material Weakness
  • 574571 2023-005
    Significant Deficiency
  • 574572 2023-001
    Material Weakness
  • 574573 2023-001
    Material Weakness
  • 574574 2023-003
    Material Weakness
  • 574575 2023-001
    Material Weakness
  • 574576 2023-002
    Material Weakness
  • 574577 2023-005
    Significant Deficiency
  • 574578 2023-001
    Material Weakness
  • 574579 2023-002
    Material Weakness
  • 574580 2023-005
    Significant Deficiency
  • 574581 2023-001
    Material Weakness
  • 574582 2023-006
    Material Weakness
  • 574583 2023-001
    Material Weakness
  • 1150925 2023-001
    Material Weakness
  • 1150926 2023-002
    Material Weakness
  • 1150927 2023-001
    Material Weakness
  • 1150928 2023-002
    Material Weakness
  • 1150929 2023-001
    Material Weakness
  • 1150930 2023-005
    Significant Deficiency
  • 1150931 2023-001
    Material Weakness
  • 1150932 2023-005
    Significant Deficiency
  • 1150933 2023-001
    Material Weakness
  • 1150934 2023-002
    Material Weakness
  • 1150935 2023-005
    Significant Deficiency
  • 1150936 2023-005
    Significant Deficiency
  • 1150937 2023-001
    Material Weakness
  • 1150938 2023-005
    Significant Deficiency
  • 1150939 2023-001
    Material Weakness
  • 1150940 2023-001
    Material Weakness
  • 1150941 2023-002
    Material Weakness
  • 1150942 2023-005
    Significant Deficiency
  • 1150943 2023-001
    Material Weakness
  • 1150944 2023-002
    Material Weakness
  • 1150945 2023-005
    Significant Deficiency
  • 1150946 2023-005
    Significant Deficiency
  • 1150947 2023-001
    Material Weakness
  • 1150948 2023-001
    Material Weakness
  • 1150949 2023-005
    Significant Deficiency
  • 1150950 2023-001
    Material Weakness
  • 1150951 2023-002
    Material Weakness
  • 1150952 2023-004
    Material Weakness
  • 1150953 2023-001
    Material Weakness
  • 1150954 2023-001
    Material Weakness
  • 1150955 2023-005
    Significant Deficiency
  • 1150956 2023-001
    Material Weakness
  • 1150957 2023-005
    Significant Deficiency
  • 1150958 2023-001
    Material Weakness
  • 1150959 2023-005
    Significant Deficiency
  • 1150960 2023-001
    Material Weakness
  • 1150961 2023-005
    Significant Deficiency
  • 1150962 2023-001
    Material Weakness
  • 1150963 2023-005
    Significant Deficiency
  • 1150964 2023-001
    Material Weakness
  • 1150965 2023-005
    Significant Deficiency
  • 1150966 2023-001
    Material Weakness
  • 1150967 2023-005
    Significant Deficiency
  • 1150968 2023-001
    Material Weakness
  • 1150969 2023-005
    Significant Deficiency
  • 1150970 2023-001
    Material Weakness
  • 1150971 2023-005
    Significant Deficiency
  • 1150972 2023-001
    Material Weakness
  • 1150973 2023-005
    Significant Deficiency
  • 1150974 2023-001
    Material Weakness
  • 1150975 2023-005
    Significant Deficiency
  • 1150976 2023-001
    Material Weakness
  • 1150977 2023-005
    Significant Deficiency
  • 1150978 2023-001
    Material Weakness
  • 1150979 2023-001
    Material Weakness
  • 1150980 2023-001
    Material Weakness
  • 1150981 2023-001
    Material Weakness
  • 1150982 2023-001
    Material Weakness
  • 1150983 2023-001
    Material Weakness
  • 1150984 2023-002
    Material Weakness
  • 1150985 2023-003
    Material Weakness
  • 1150986 2023-002
    Material Weakness
  • 1150987 2023-001
    Material Weakness
  • 1150988 2023-001
    Material Weakness
  • 1150989 2023-005
    Significant Deficiency
  • 1150990 2023-001
    Material Weakness
  • 1150991 2023-005
    Significant Deficiency
  • 1150992 2023-001
    Material Weakness
  • 1150993 2023-005
    Significant Deficiency
  • 1150994 2023-001
    Material Weakness
  • 1150995 2023-002
    Material Weakness
  • 1150996 2023-005
    Significant Deficiency
  • 1150997 2023-001
    Material Weakness
  • 1150998 2023-005
    Significant Deficiency
  • 1150999 2023-001
    Material Weakness
  • 1151000 2023-005
    Significant Deficiency
  • 1151001 2023-001
    Material Weakness
  • 1151002 2023-002
    Material Weakness
  • 1151003 2023-001
    Material Weakness
  • 1151004 2023-002
    Material Weakness
  • 1151005 2023-001
    Material Weakness
  • 1151006 2023-005
    Significant Deficiency
  • 1151007 2023-002
    Material Weakness
  • 1151008 2023-001
    Material Weakness
  • 1151009 2023-002
    Material Weakness
  • 1151010 2023-001
    Material Weakness
  • 1151011 2023-001
    Material Weakness
  • 1151012 2023-001
    Material Weakness
  • 1151013 2023-005
    Significant Deficiency
  • 1151014 2023-001
    Material Weakness
  • 1151015 2023-001
    Material Weakness
  • 1151016 2023-003
    Material Weakness
  • 1151017 2023-001
    Material Weakness
  • 1151018 2023-002
    Material Weakness
  • 1151019 2023-005
    Significant Deficiency
  • 1151020 2023-001
    Material Weakness
  • 1151021 2023-002
    Material Weakness
  • 1151022 2023-005
    Significant Deficiency
  • 1151023 2023-001
    Material Weakness
  • 1151024 2023-006
    Material Weakness
  • 1151025 2023-001
    Material Weakness
  • 1151026 2023-006
    Material Weakness

Programs in Audit

ALN Program Name Expenditures
21.027 Coronavirus State and Local Fiscal Recovery Funds $1.40M
93.391 Covid-19 Activities to Support State, Tribal, Local and Territorial (stlt) Health Department Response to Public Health Or Healthcare Crisis $1.26M
93.394 Cancer Detection and Diagnosis Research $816,528
21.027 Covid-19 Coronavirus State and Local Fiscal Recovery Funds $609,195
93.310 Trans-Nih Research Support $313,490
93.889 National Bioterrorism Hospital Preparedness Program $270,452
16.560 National Institute of Justice Research, Evaluation, and Development Project Grants $187,525
93.323 Covid-19 Epidemiology and Laboratory Capacity for Infectious Diseases (elc) $167,045
93.350 National Center for Advancing Translational Sciences $164,703
93.994 Maternal and Child Health Services Block Grant to the States $119,852
93.368 21st Century Cures Act - Precision Medicine Initiative $94,609
93.838 Lung Diseases Research $93,061
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $80,571
93.855 Allergy and Infectious Diseases Research $72,630
93.351 Research Infrastructure Programs $67,407
93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health $64,097
93.396 Cancer Biology Research $56,813
12.420 Military Medical Research and Development $55,493
93.226 Research on Healthcare Costs, Quality and Outcomes $36,564
93.865 Child Health and Human Development Extramural Research $29,653
93.393 Cancer Cause and Prevention Research $17,681
93.307 Minority Health and Health Disparities Research $15,122
93.172 Human Genome Research $15,121
93.397 Cancer Centers Support Grants $14,078
93.866 Aging Research $11,855
93.273 Alcohol Research Programs $10,732
14.218 Community Development Block Grants/entitlement Grants $10,044
93.837 Cardiovascular Diseases Research $8,921
93.361 Nursing Research $7,645
93.667 Social Services Block Grant $7,551
93.839 Blood Diseases and Resources Research $3,217
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $597
93.395 Cancer Treatment Research $512
93.946 Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs $-697
93.859 Biomedical Research and Research Training $-2,184
93.242 Mental Health Research Grants $-20,481